Natalie Holles
2018 - Audentes Therapeutics
In 2018, Natalie Holles earned a total compensation of $1.2M as President and Chief Operating Officer at Audentes Therapeutics, a 66% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $163,800 |
|---|---|
| Option Awards | $611,413 |
| Salary | $448,211 |
| Total | $1,223,424 |
Holles received $611.4K in option awards, accounting for 50% of the total pay in 2018.
Holles also received $163.8K in non-equity incentive plan and $448.2K in salary.
Rankings
In 2018, Natalie Holles' compensation ranked 8,190th out of 14,244 executives tracked by ExecPay. In other words, Holles earned more than 42.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,190 out of 14,244 | 43rd |
Division Manufacturing | 3,238 out of 5,765 | 44th |
Major group Chemicals And Allied Products | 1,216 out of 2,128 | 43rd |
Industry group Drugs | 1,016 out of 1,817 | 44th |
Industry Biological Products, Except Diagnostic Substances | 192 out of 339 | 43rd |
Source: SEC filing on April 26, 2019.
Holles' colleagues
We found four more compensation records of executives who worked with Natalie Holles at Audentes Therapeutics in 2018.